Treatment of Advanced Non-small-cell Lung Cancer in Special Populations
Overview
Authors
Affiliations
The benefits of chemotherapy in non-small-cell lung cancer (NSCLC) patients remains, to some extent, restricted to younger patients with a good performance status (PS). It has long been assumed that chemotherapy is too toxic and of marginal benefit for elderly NSCLC patients and those with a PS of 2. Nevertheless, retrospective analyses and more recent prospective trials have suggested that such patients enjoy longer survival and a better quality of life when treated with chemotherapy. This article will review the data and discuss their clinical implications.
Malapelle U, Rossi A, Bria E J Thorac Dis. 2019; 11(Suppl 15):S1837-S1840.
PMID: 31632763 PMC: 6783785. DOI: 10.21037/jtd.2019.08.99.
Choi J, Choi J, Chung S, Oh J, Lee Y, Min K Tuberc Respir Dis (Seoul). 2019; 82(3):211-216.
PMID: 30841020 PMC: 6609518. DOI: 10.4046/trd.2018.0019.
Factors influencing treatment selection and survival in advanced lung cancer.
Tabchi S, Kassouf E, Florescu M, Tehfe M, Blais N Curr Oncol. 2017; 24(2):e115-e122.
PMID: 28490934 PMC: 5407874. DOI: 10.3747/co.24.3355.
Fujimoto D, Kato R, Morimoto T, Shimizu R, Sato Y, Kogo M PLoS One. 2016; 11(12):e0168465.
PMID: 28006019 PMC: 5179067. DOI: 10.1371/journal.pone.0168465.
ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country.
Noronha V, Ramaswamy A, Patil V, Joshi A, Chougule A, Kane S PLoS One. 2016; 11(9):e0160752.
PMID: 27637025 PMC: 5026380. DOI: 10.1371/journal.pone.0160752.